Moderna’s COVID-19 vaccine could be up to 94.5% effective, late-stage Phase 3 trial finds

Moderna’s COVID-19 vaccine could be up to 94.5% effective, late-stage Phase 3 trial finds


NEW YORK — Moderna is revealing very good efficacy data in their late-stage Phase 3 trial.

The interim analysis shows Moderna’s vaccine could be up to 94.5% effective. The company plans to ask the FDA for authorization “in the coming weeks” after safety data is available. This puts them on track…



Source: abc7ny.com. Read more —>

Related Articles